Agenda for Day 2 - Tuesday 10 November, 2026Tuesday, 10 November 2026

As geopolitical pressures, supply chain vulnerabilities, and shifting capital dynamics reshape the life sciences landscape, resilience has emerged as the defining principle for how biopharma operates and grows. The era of purely global, efficiency-driven partnerships is giving way to a more complex reality—one where strategic alliances must balance speed, scale, and security.

In this plenary session, leaders from WuXi AppTec and Evotec are joined by voices from global pharma and investment to explore how partnerships are being redefined across the value chain. From discovery through development and manufacturing, the discussion will examine how companies are adapting their collaboration models to navigate fragmentation while maintaining innovation momentum.

Together, they will address critical questions facing the industry: How can biopharma build resilient, future-proof alliances without sacrificing efficiency? What does strategic alignment look like in an era of regionalization and rising geopolitical complexity? And how will capital, capability, and control shape the next generation of partnerships?

Bringing perspectives from infrastructure, platform biotech, pharma, and investment, this session offers a forward-looking view on how the industry can move from reactive risk management to resilience by design—rebuilding the foundations of collaboration for a more uncertain, but opportunity-rich future.

Why now? The time is now. Must be positioned as a systemic market failure and the biggest commercial opportunity of the next decade.This is not about representation/feminism. It’s about missed revenue, broken clinical models, and outdated investment theses. This is not niche, its macro

Macro question:
How much value has the industry left on the table by designing healthcare around the wrong default patient?